Pathogen-specific risk of seizure in children with moderate-to-severe diarrhoea: Case control study with follow-up

Farzana Afroze1, Sumon Kumar Das2,3, Shahnawaz Ahmed4

  • 1Nutrition & Clinical Services Division, International Centre for Diarrhoeal Disease Research, Dhaka, Bangladesh.

Abstract

Insights

Shigellosis and norovirus infections significantly increase seizure risk in children with moderate-to-severe diarrhea (MSD). Early diagnosis and treatment of shigellosis can prevent seizure complications in MSD cases.

Area of Science:

  • Infectious Diseases
  • Pediatrics
  • Epidemiology

Background:

  • Moderate-to-severe diarrhea (MSD) is a significant health concern in children under five.
  • Seizures are a serious complication of diarrheal illnesses in young children.
  • Identifying specific pathogens linked to seizures in MSD is crucial for targeted interventions.

Purpose of the Study:

  • To determine the pathogen-specific risk factors for seizures in hospitalized children under five with moderate-to-severe diarrhea (MSD).
  • To investigate the association between specific enteric pathogens and seizure occurrence in pediatric MSD cases.

Main Methods:

  • A prospective case-control study was conducted in a rural Bangladeshi setting.
  • Cases were children aged 0-59 months with MSD and seizure; controls were children with MSD but no seizure.
  • Logistic regression analysis was used to identify independent risk factors for seizure.

Main Results:

  • Shigellosis (particularly S. flexneri and S. sonnei), norovirus, fever, and loss of consciousness were identified as independent risk factors for seizure in MSD children.
  • Shigellosis showed a significantly elevated odds ratio (OR=5.34) for seizure.
  • Cases exhibited lower Weight-for-Height Z-score (WHZ) at enrollment compared to controls.

Conclusions:

  • Childhood MSD episodes, especially those caused by Shigella and norovirus, are frequently associated with seizures.
  • Prompt identification and management of shigellosis in children with MSD can potentially reduce the incidence and severity of associated seizures.

Related Concept Videos

Epilepsy and Seizures: Overview01:24

Epilepsy and Seizures: Overview

Epilepsy is a chronic neurological disease marked by recurrent, unpredictable seizures. These seizures are caused by abnormal electrical discharges in the brain, leading to behavior, sensation, or consciousness alterations. They can also cause transient impairment of awareness, interfering with daily activities.
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
1.0K
Seizures: Classification01:13

Seizures: Classification

Epilepsy is primarily characterized by unpredictable seizures, either provoked by an identifiable factor, such as injury or illness, or unprovoked, occurring spontaneously without apparent cause.
Seizures are typically classified into two main categories: focal and generalized seizures.
Focal Seizures
Focal seizures originate from specific regions of the brain. These seizures are further sub-classified into two types:
1.2K
Drugs Affecting GI Tract Motility: Antimicrobials as Antidiarrheal Agents01:18

Drugs Affecting GI Tract Motility: Antimicrobials as Antidiarrheal Agents

Acute diarrhea, a common gastrointestinal disturbance, is characterized by the rapid evacuation of fluid stools, leading to an excessive weight in fluid. This condition typically arises from disorders affecting intestinal water and electrolyte transport. It can be triggered by an increased osmotic load within the intestine, excessive secretion of electrolytes and water, mucosal exudation of protein and fluid, or altered intestinal motility. The primary risks of acute diarrhea are dehydration...
363
Drugs for Treatment of Diarrhea-Predominant IBS01:17

Drugs for Treatment of Diarrhea-Predominant IBS

Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
524
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein01:20

Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein

Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
716
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
167